Neuroscience Institute Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Conditions:

Cerebral Palsy, Dyskinesia

Principal Investigator:

Migvis Monduy

Learn more at: https://clinicaltrials.gov/study/NCT05206513

Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the US

Conditions:

Niemann-Pick

Principal Investigator:

Paula Schleifer

Learn more at: https://clinicaltrials.gov/study/NCT04316637

Clinical Needs of Individuals with a Chromosome 15 Condition

Conditions:

Angelman Syndrome

Principal Investigator:

Paula Schleifer

TSC Alliance Tuberous Sclerosis Complex (TSC) Biosample Repository and Natural History Database

Conditions:

Tuberous Sclerosis, Lymphangioleiomyomatosis

Principal Investigator:

Paula Schleifer

Learn more at: https://clinicaltrials.gov/study/NCT05676099

A Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam in Study Participants with Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Conditions:

Epilepsy

Principal Investigator:

Anuj Jayakar

Learn more at: https://clinicaltrials.gov/study/NCT06315322

A Safety and Feasibility Study to Evaluate Blood Brain Barrier Disruption Using Exablate MR Guided Focused Ultrasound in Combination With Doxorubicin in Treating Pediatric Patients With Diffuse Intrinsic Pontine Gliomas (DIPG)

Conditions:

Brain Tumor

Principal Investigator:

Toba Niazi

Learn more at: https://clinicaltrials.gov/study/NCT05630209

A Phase 4, Interventional, Multicenter, Open-Label, Single-Arm Study to Assess Behavioral and Other Co-occurring Outcomes Following Treatment With EPID(I/Y)OLEX as Add-on Therapy in Participants (Aged 1 to 65 Years Old) With Seizures Associated With Tuberous Sclerosis Complex

Conditions:

Tuberous Sclerosis

Principal Investigator:

Paula Schleifer

Learn more at: https://clinicaltrials.gov/study/NCT05864846

Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

Principal Investigator:

Wilson Heredia-Nunez

Learn more at: https://clinicaltrials.gov/study/NCT04649242

Focal Cerebral Arteriopathy Steroid Trial

Conditions:

Stroke, Arteriopathy, Arterial Ischemic Stroke

Principal Investigator:

Anuj Jayakar

Learn more at: https://clinicaltrials.gov/study/NCT06040255

A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Conditions:

Absence Epilepsy

Principal Investigator:

Anuj Jayakar

Learn more at: https://clinicaltrials.gov/study/NCT04666610

A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome

Conditions:

Angelman Syndrome

Principal Investigator:

Paula Schleifer

Learn more at: https://clinicaltrials.gov/study/NCT06617429